Immodulon is a private, late-stage clinical company that specializes in developing safe and effective immunotherapy treatments. Their flagship product, IMM-101, is a novel broad spectrum immuno modulator that works by inducing a broad immune response and modulating the innate and adaptive immune systems. This makes IMM-101 a complement to existing cancer therapies, including immune checkpoint inhibitors and chemotherapy.

Notably, IMMOD-101 has shown promising results in first-line patients with advanced pancreatic ductal adenocarcinoma (PDAC) when used in combination with gemcitabine. The data indicates that IMM-101 is well-tolerated and effective, with the potential to prolong progression-free survival and improve overall survival rates. Immodulon is now planning a pivotal study to further evaluate the benefits of IMM-101 in metastatic PDAC patients.

Led by a highly experienced and successful management team, Immodulon is focused on realizing the significant potential of IMM-101 in treating difficult-to-treat cancers